Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Mo Jain_2024
Expanding Services: Mo Jain Sheds Light on Sapient’s Recently Launched Discovery Proteomics Services
Shots:  Following the roll-out of high throughput discovery proteomics services, Mo Jain, Founder and CEO of Sapient engages in a stimulating conversation with PharmaShots  Unlike conventional mass spectrometry-based proteomics methodologies in the market, Sapient’s Discovery Proteomics Services leverage the nanoparticle enrichment technology to measure more proteins and PTMs within the plasma proteome  While highlighting Sapient’s…
April 16, 2024
VIEWPOINTS_Neal Shore_2024
Bayer at ASCO GU: Neal Shore Speaking about Nubeqa with PharmaShots
Shots:   At ASCO GU, Bayer presented new data from its Oncology portfolio. The analysis revolved around NUBEQA (darolutamide), which is currently approved in the US in combination with docetaxel for the treatment of mHSPC and nmCRPC in adults   Neal Shore in conversation with PharmaShots initiated the discussion by familiarizing our audience with the ARASENS P-III…
April 10, 2024
VIEWPOINTS_Kari Wong_2024
Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN
Shots:   Following the strategic collaboration with the Sheffield Institute for Translational Neuroscience (SITraN), Metabolon’s scientific strategic director Kari Wong, engages in an illuminating conversation with PharmaShots    The collaboration aims to enhance the understanding of ALS and motor neuron disease (MND) by integrating a comprehensive biomarker approach to provide better diagnostics and therapeutics for these challenging…
April 8, 2024
VIEWPOINTS_Ofer Gonen_2024
Fund Secured: MediWounds’ CEO Ofer Gonen in Conversation with PharmaShots
Shots:  Ofer Gonen, CEO at MediWound, in conversation with PharmaShots, sheds light on recent funding from the US Department of Defence to further develop NexoBrid for the US Army  NexoBrid an FDA-approved enzymatic therapy to treat severe burns is jointly developed by Vericel and received US FDA approval in Dec’22  MediWound secured an additional $6.7M…
April 4, 2024
VIEWPOINTS_Ahsan Arozullah_2024
A New Hope in Bladder Cancer Combination Therapy: PharmaShots in Conversation with Ahsan Arozullah
Shots:  Transformative combination therapies add wonder to oncology therapeutics now and then. Dr. Ahsan Arozullah, in another engaging conversation with PharmaShots, talks about Padcev + Keytruda therapy for adult patients suffering from locally advanced or metastatic urothelial cancer (la/mUC)  Ahsan shares insights from the P-III (EV-302) trial based on which the FDA accepted Padcev +…
April 2, 2024
VIEWPOINTS_David Jackson_2024
SEA Management with Fasenra: David Jackson & Fasenra Team (AZ) Share Insights from the SHAMAL P-IV Study
Shots:  David Jackson and AstraZeneca’s Fasenra Team, in an engaging conversation with PharmaShots highlight the key findings from the SHAMAL P-IV study  SHAMAL is the first-ever prospective study that investigated the potential of targeted biologic treatment to enable a significant step down of inhaled corticosteroid (ICS) therapy in severe asthma patients  SHAMAL showcased that ICS…
March 20, 2024
VIEWPOINTS_Richard Stefanacci_2024
Neurogenerative Disorders Management: Richard Stefanacci of TauRx in an Enlightening Conversation with PharmaShots
Shots:  Richard Stefanacci, Chief Medical Officer at TauRx, sheds light on the anti-tau drug Hydronomethylthionine mesylate (HMTM), a potential oral treatment for patients with Alzheimer’s disease and mild cognitive impairment  While highlighting the positive results from the LUCIDITY P-III study, Richard speaks about bridging the gap in AD and MCI treatment by lowering the dependence…
March 18, 2024
VIEWPOINTS_Susan Pandya_2024
Servier at SNO 2023: Dr. Susan Pandya Sheds Light on IDH-Mutant Diffuse Glioma Management
Shots:  In a stimulating conversation with PharmaShots, Dr. Susan Pandya shares insights from their presentation at SNO 2023 to strengthen Servier’s Neuro-Oncology Profile  While highlighting the details of vorasidenib, Susan articulately explains the study design of the P-III Indigo trial evaluating vorasidenib in patients with IDH-mutant diffuse glioma  With a fast-track designation and breakthrough therapy…
March 7, 2024
VIEWPOINTS_Philip M. Brown1_G. Michael Lewitt2_2024
Treating Plaque Psoriasis with VTAMA: Dermavant ‘s Philip M. Brown & G. Michael Lewitt in Conversation with PharmaShots
Shots:  G. Michael Lewitt and Philip M.Brown enlightened PharmaShots’ audience on Dermavant Sciences’ VTAMA cream a first-in-its-class topical prescription medication approved for Plaque Psoriasis  Michael & Philip discussed VTAMA’s study design along with its MOA, ROA, and formulation while shedding light on P-IV data  Philip further goes ahead to share details on VTAMA’s ongoing study…
February 29, 2024
Load more